A Study to Evaluate Efficacy and Safety of Obinutuzumab in Patients with Primary Membranous Nephropathy

You likely can't join if

• Uncontrolled blood pressure, in the opinion of the investigator, during 3 months prior to screening
• Evidence of >= 50% reduction in proteinuria during the previous 6 months prior to randomization
• Receipt of renal replacement therapy
• Type 1 or 2 diabetes mellitus
• Receipt of previous therapies as follows: - Treatment with MMF or oral, intramuscular, or intravenous corticosteroids within 1 month prior to or during screening - Any B-cell depleting therapy such as rituximab, ocrelizumab, or ofatumumab within 9 months prior to or during screening - Treatment with cyclophosphamide or CNI within 6 months prior to or during screening - Treatment with any biologic therapy such as belimumab, ustekinumab, or anifrolumab within 6 months prior to or during screening - Treatment with an inhibitor of Janus-associated kinase, Bruton’s tyrosine kinase, or tyrosine kinase 2, including but not limited to tofacitinib, baricitinib, upadacitinib, filgotinib, ibrutinib, or fenebrutinib within 3 months prior to or during screening - Treatment with any investigational agent within 28 days of screening or 5 drug-elimination half-lives of the investigational drug, whichever is longer - Receipt of a live vaccine within 28 days prior to screening or during screening
• Patients with a secondary cause of MN (e.g., hepatitis B, SLE, medications, malignancies)